Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Canopy Growth Corp    CGC   CA1380351009

CANOPY GROWTH CORP (CGC)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Canopy Growth : comments on Federal Excise Tax Proposal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:53pm CET

SMITHS FALLS, ON, Nov. 10, 2017 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") has been a longtime vocal proponent of a fair and reasonable tax rate that funds important programs needed to successfully transition cannabis out of prohibition. To this point, the Company has spent almost $1-million on its core CSR initiatives over the past three years in key policy areas; research, road safety, and youth education, and commits $1 from the sale of every bottle of cannabis oil to education projects.

The Company's efforts include funding for important research initiatives such as the Quebec Cannabis Registry, funding a series of PSAs in partnership with MADD Canada and the Canadian Drug Policy Coalition, and committing funding to Parent Action on Drugs and Canadian Students for Sensible Drug Policy to support cannabis-specific education initiatives designed for parents looking for resources to help them talk to their children about responsible choices.  

Today's proposed rate, ten percent on top of existing HST falls within the limit of an acceptable tax framework and is in line with Management's expectation. The proposed rate should allow Canopy Growth and other industry players of various sizes to compete with the black market on price point. Canopy Growth also strongly supports a system that sees the federal and provincial governments collaborate on taxation source and structure. A consistent rate across the country is preferable and would give the Company the confidence it needs to continue creating jobs and investing hundreds of millions of dollars across Canada.

While in some ways the Company understands the policy rationale of including taxation on medical cannabis sales, it is unfortunate that despite Canopy Growth's ongoing advocacy efforts on the subject cannabis will continue to be the only physician-authorized drug in the country subject to sales tax. This is an unfair tax burden on chronically ill Canadians and only further reinforces the need for government, industry and patients to work together to obtain insurance coverage for authorized medical cannabis patients. To that end Canopy Growth is hopeful that revenue from cannabis taxation is earmarked for research to accelerate the Drug Identification Number approval process which is seen as the key to medical insurance coverage for cannabis-based medicines.

Here's to Future Growth.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of GMP-certified indoor and greenhouse production capacity, all to an unparalleled level of quality assurance procedures and testing. Canopy Growth has established partnerships with leading sector names in Canada and abroad, with interests and operations spanning four continents.  The Company is proudly dedicated to educating healthcare practitioners, providing consistent access to high quality cannabis products, conducting robust clinical research, and furthering the public's understanding of cannabis. For more information visit www.canopygrowth.com.  

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Canopy Growth Corporation

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CANOPY GROWTH CORP
02/19CANOPY GROWTH : signs letter of intent with Societe des alcools du Quebec
AQ
02/16IIROC Trade Halt - Canopy Growth Corporation
NE
02/16CANOPY GROWTH : IIROC Trade Halt - Canopy Growth Corporation
AQ
02/16CANOPY GROWTH : IIROC Trading Halt - WEED
AQ
02/16DELTA 9 CANNABIS : and Canopy Earn Retail License in Manitoba
AQ
02/16CANOPY GROWTH : successful in bid to operate private retail stores in Manitoba
AQ
02/16Pot Pharm - Booming Canada weed sector plots next-wave medicines
RE
02/16POT PHARM : Booming Canada weed sector plots next-wave medicines
RE
02/15CANOPY GROWTH CORPORATION : issues common shares
AQ
02/14CANOPY GROWTH : Who is cashing in on Canada's marijuana 'Green Rush'?
AQ
More news
News from SeekingAlpha
02/17Cannabis Winners And Losers In Manitoba And Quebec 
02/16Canopy Clinched Quebec Victory 
02/14APHRIA : Major Uncertainty Removed 
02/13AURORA CANNABIS : Firing On All Cylinders 
02/13The S-Curve Reveals It Is Early Days In The Marijuana Growth Cycle 
Financials ( CAD)
Sales 2018 83,3 M
EBIT 2018 -34,0 M
Net income 2018 -30,7 M
Finance 2018 359 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 227,08
EV / Sales 2018 58,7x
EV / Sales 2019 15,2x
Capitalization 5 250 M
Chart CANOPY GROWTH CORP
Duration : Period :
Canopy Growth Corp Technical Analysis Chart | CGC | CA1380351009 | 4-Traders
Technical analysis trends CANOPY GROWTH CORP
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 33,1  CAD
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Mark Zekulin President
Bruce Linton Chairman
Timothy R. Saunders Chief Financial Officer & Senior Vice President
Christopher James Schnarr Director
John K. Bell Lead Director
Sector and Competitors